Literature DB >> 15531967

Open surgery induces a dramatic decrease in circulating intact IGFBP-3 in patients with colorectal cancer not seen with laparoscopic surgery.

I Kirman1, V Cekic, N Poltoratskaia, P Sylla, S Jain, K A Forde, R L Whelan.   

Abstract

BACKGROUND: As shown earlier by the authors via Western blot analysis, open (OS) but not laparoscopic surgery (LS) induces a qualitative decrease in plasma insulin-like growth factor-binding protein 3 (IGFBP-3) levels on postoperative day 1 (POD 1). Intact IGFBP-3 has tumor suppressive effects, but its degradation products do not. Enzyme linked immunoassay (ELISA) inevitably measures both. In this study, using a novel combined Western blot and ELISA analysis method, precise plasma levels of intact IGFBP-3 on POD2 after open and closed colorectal cancer resection (stage I-III) were determined.
METHODS: This study included 15 OS patients with a mean incision length of 26.7 +/- 15.5 cm and 16 LS patients with a mean incision length of 5.3 +/- 3.1 cm. Intact IGFBP-3 levels were determined via ELISA and Western blot analysis in plasma collected preoperatively and postoperatively.
RESULTS: In the OS patients, the mean preoperative concentration of intact 43-45 kDa IGFBP-3 protein was 1920 +/- 1430 ng/ml. It decreased dramatically on POD2 to 355 +/- 545 ng/ml (p < 0.005). In the LS group, no significant difference was noted between the preoperative level (1305 +/- 807 ng/ml) and the POD2 level (922 + 714 ng/ml).
CONCLUSIONS: Open cancer resection, unlike its minimally invasive alternative, induces a dramatic decrease in concentration of intact IGFBP-3, which may have important implications with regard to colon cancer recurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531967     DOI: 10.1007/s00464-004-8906-x

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  24 in total

1.  Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner.

Authors:  Z P Gill; C M Perks; P V Newcomb; J M Holly
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Circulating insulin-like growth factor II and colorectal adenomas.

Authors:  A G Renehan; J E Painter; D O'Halloran; W S Atkin; C S Potten; S T O'Dwyer; S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

3.  Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins.

Authors:  R C Baxter; J L Martin; M I Tyler; M E Howden
Journal:  Biochem Biophys Res Commun       Date:  1986-09-30       Impact factor: 3.575

4.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

Authors:  J Ma; M N Pollak; E Giovannucci; J M Chan; Y Tao; C H Hennekens; M J Stampfer
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

5.  IGFBP-3 binding to endothelial cells inhibits plasmin and thrombin proteolysis.

Authors:  B A Booth; M Boes; B L Dake; K L Knudtson; R S Bar
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-01       Impact factor: 4.310

6.  Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1.

Authors:  B J Boyle; X Y Zhao; P Cohen; D Feldman
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

7.  Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells.

Authors:  Jiang Hong; George Zhang; Feng Dong; Matthew M Rechler
Journal:  J Biol Chem       Date:  2002-01-09       Impact factor: 5.157

8.  Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity.

Authors:  M L Cubbage; A Suwanichkul; D R Powell
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

9.  Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment.

Authors:  H Grønbek; T Thøgersen; J Frystyk; H Vilstrup; A Flyvbjerg; J F Dahlerup
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

10.  IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding, and structure of fragments.

Authors:  B A Booth; M Boes; R S Bar
Journal:  Am J Physiol       Date:  1996-09
View more
  15 in total

1.  Magnetically anchored camera and percutaneous instruments maintain triangulation and improve cosmesis compared with single-site and conventional laparoscopic cholecystectomy.

Authors:  Nabeel A Arain; Luisangel Rondon; Deborah C Hogg; Jeffrey A Cadeddu; Richard Bergs; Raul Fernandez; Daniel J Scott
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

2.  Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer.

Authors:  I Kirman; S Jain; V Cekic; A Belizon; E Balik; P Sylla; T Arnell; K A Forde; R L Whelan
Journal:  Surg Endosc       Date:  2006-01-21       Impact factor: 4.584

3.  Impact of minimally invasive techniques in colorectal surgery.

Authors:  Tonia M Young-Fadok
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

4.  Why the Resistance: Minimally Invasive Pancreaticoduodenectomy-Saving the Patient from Tigers.

Authors:  Brij B Agarwal; Neeraj Dhamija; Shruti Sharma; Sneh Agarwal
Journal:  Indian J Surg       Date:  2016-12-13       Impact factor: 0.656

5.  Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods.

Authors:  Avraham Belizon; Emre Balik; Daniel L Feingold; Marc Bessler; Tracey D Arnell; Kenneth A Forde; Patrick K Horst; Suvinit Jain; Vesna Cekic; Irena Kirman; Richard L Whelan
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

6.  Long-term results of laparoscopic versus open colorectal resections for cancer in 235 patients with a minimum follow-up of 5 years.

Authors:  E Lezoche; M Guerrieri; A De Sanctis; R Campagnacci; M Baldarelli; G Lezoche; A M Paganini
Journal:  Surg Endosc       Date:  2006-02-27       Impact factor: 4.584

7.  Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.

Authors:  H M C Shantha Kumara; A Hoffman; I Y Kim; D Feingold; N Dujovny; M Kalady; M Kallady; M Luchtefeld; R L Whelan
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

8.  Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.

Authors:  A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan
Journal:  Surg Endosc       Date:  2008-01-18       Impact factor: 4.584

9.  Laparoscopic versus open colectomy for TNM stage III colon cancer: results of a prospective multicenter study in Italy.

Authors:  Mario Guerrieri; Roberto Campagnacci; Angelo De Sanctis; Giovanni Lezoche; Paolo Massucco; Massimo Summa; Rosaria Gesuita; Lorenzo Capussotti; Giuseppe Spinoglio; Emanuele Lezoche
Journal:  Surg Today       Date:  2012-08-19       Impact factor: 2.549

Review 10.  Minimally invasive surgery and cancer: controversies part 1.

Authors:  Melanie Goldfarb; Steven Brower; S D Schwaitzberg
Journal:  Surg Endosc       Date:  2009-07-02       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.